Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 177 projects in pharma, of which 69 are active.
Of the active ones, 37 expansion, 29 new construction and 3 revamp / retrofit.
24 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
The 68-week REDEFINE 9 study compared two dose levels with placebo in 309 adults with overweight or obesity without diabetes.
The subcutaneous treatment offers monthly, every-two-weeks or weekly prophylaxis via a single-use pre-filled pen.
The European Commission is expected to decide within two months; the US review has a March 22, 2027 target action date.
A European Commission decision is expected within two months. Phase 3 data showed a 26% lower risk of progression or death versus cabozantinib.
The recommendation covers people vaccinated at least two years earlier; EU authorisation is still pending.
The committee also backed 11 indication extensions, issued guidance on Mounjaro and confirmed two refusals after re-examination.
The proposed add-on use targets adults whose disease remains active despite standard therapy and who test positive for specified antibodies.
The applications draw on Phase 3 HIBISCUS results, including a 27% reduction in vaso-occlusive crises versus placebo.
In the phase III trial, 76.7% of treated patients achieved an SRI-4 response at 52 weeks, versus 53.5% on placebo.
The oral OX2R agonist is a Schedule IV controlled substance and will be dispensed through Accredo Specialty Pharmacy.
active all projects
The 8 with the most active projects, of 27 countries.
